Finance

Beta
Lists
SABS:NASDAQ
SAB Biotherapeutics Inc
$3.92
+1.03%
(+0.040) 1D
$3.92
0.00% (0.00)
After hours
Closed: Jul 2, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SABS...
Open
$3.91
High
$4.04
Low
$3.85
Mkt. cap
299.74M
Avg. vol.
896.48K
Volume
266.62K
52-wk high
$6.60
52-wk low
$1.72
EPS
-$1.43
Beta
0.52
Shares outstanding
76.46M
No. of employees
86
Open
$3.91
High
$4.04
Low
$3.85
Mkt. cap
299.74M
Avg. vol.
896.48K
Volume
266.62K
52-wk high
$6.60
52-wk low
$1.72
EPS
-$1.43
Beta
0.52
Shares outstanding
76.46M
No. of employees
86
News stories
From sources across the web
About SAB Biotherapeutics Inc
CEO-
Employees86
Founded2014
HeadquartersMiami Beach, Florida, United States
SectorBiotechnology
Websitesab.bio
Analyst ratings
Based on 8 analysts giving stock ratings to SABS in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for SABS in the last 3 months.
Highest
Current $3.92
$16.00 (+308.16%)
Average
$12.00 (+206.12%)
Lowest
$6.00 (+53.06%)
Analyst
Recommendation
Action
Price target
Projected
Date
Eliana Merle
Barclays
Buy
Initiated
$13.00
+231.6%
06/24/2026
Keay Nakae
Chardan Capital
Buy
Reiterated
$16.00
+308.2%
06/16/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
$6.00
+53.1%
06/16/2026
Samantha Semenkow
Citi
Buy
Reiterated
$11.00
+180.6%
06/15/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
$14.00
+257.1%
06/15/2026
Emily Bodnar
H.C. Wainwright
Buy
Reiterated
$10.00
+155.1%
06/15/2026
Roger Song
Jefferies
Buy
Initiated
$11.00
+180.6%
05/20/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$15.00
+282.7%
05/13/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
$13.00
+231.6%
04/02/2026
Michael Yee
UBS
Buy
Maintained
$7.00
+78.6%
02/25/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
7.00M
8.97M
9.73M
13.40M
Cost of revenue
7.00M
8.97M
9.73M
13.40M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.74M
3.71M
6.04M
6.60M
Operating expense
2.74M
3.71M
6.04M
6.60M
Total operating expenses
9.73M
12.68M
15.77M
20.00M
Operating income
-9.73M
-12.68M
-15.77M
-20.00M
Other non operating income
-331.43K
57.51M
-1.73M
144.40K
EBT including unusual items
-10.11M
45.45M
-16.86M
-18.87M
EBT excluding unusual items
-10.11M
45.45M
-16.86M
-18.87M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-10.11M
45.45M
-16.86M
-18.87M
Net profit margin
-
-
-
-
Earnings per share
-
-
-0.41
-
Interest and investment income
13.56K
655.23K
700.74K
1.05M
Interest expense
-64.34K
-43.29K
-63.46K
-62.74K
Net interest expenses
-50.78K
611.94K
637.28K
984.45K
Depreciation and amortization charges
-
-
-
-
EBITDA
-8.96M
-11.91M
-15.01M
-19.25M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer